Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ: MGTX )

6.170 +0.080 (+1.31%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 79,857
Open 6.090
Bid (Size) 5.500 (2)
Ask (Size) 6.750 (6)
Prev. Close 6.090
Today's Range 6.020 - 6.210
52wk Range 3.850 - 7.600
Shares Outstanding 78,153,401
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire

Performance

YTD
-15.83%
-15.83%
1 Month
-2.53%
-2.53%
3 Month
+51.97%
+51.97%
6 Month
+44.84%
+44.84%
1 Year
-13.71%
-13.71%

More News

Read More
Jim Cramer: This Tech Stock Is A Buy, SoFi Technologies Is Good
Via Benzinga
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
From MeiraGTx
Via GlobeNewswire
Recap: MeiraGTx Hldgs Q4 Earnings
Via Benzinga
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
Via Benzinga
Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints
Via Benzinga
Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views
Via Benzinga
Exposures Fossil Fuels
Walgreens Posts Upbeat Earnings, Joins Wolfspeed, Ericsson And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
From MeiraGTx
Via GlobeNewswire
MGTX Stock Earnings: MeiraGTx Hldgs Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
From MeiraGTx
Via GlobeNewswire
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose
Via Benzinga
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
From MeiraGTx
Via GlobeNewswire
MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals
From MeiraGTx
Via GlobeNewswire
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.